BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31698454)

  • 21. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
    Xue F; Li H; Wu X; Liu W; Zhang F; Tang D; Chen Y; Wang W; Chi Y; Zheng J; Du Z; Jiang W; Zhong C; Wei J; Zhu P; Fu R; Liu X; Chen L; Pei X; Sun J; Cheng T; Yang R; Xiao X; Zhang L
    Lancet Haematol; 2022 Jul; 9(7):e504-e513. PubMed ID: 35598604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.
    Majowicz A; Nijmeijer B; Lampen MH; Spronck L; de Haan M; Petry H; van Deventer SJ; Meyer C; Tangelder M; Ferreira V
    Mol Ther Methods Clin Dev; 2019 Sep; 14():27-36. PubMed ID: 31276009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
    Miesbach W; Sawyer EK
    Hum Gene Ther Clin Dev; 2018 Jun; 29(2):80-89. PubMed ID: 29624465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemgenix - A gene therapy for hemophilia B.
    Med Lett Drugs Ther; 2023 Jan; 65(1668):9-10. PubMed ID: 36651790
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia.
    Thornburg CD; Simmons DH; von Drygalski A
    BioDrugs; 2023 Sep; 37(5):595-606. PubMed ID: 37490225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid.
    Zemplenyi A; Leonard J; DiStefano MJ; Anderson KE; Wright GC; Mendola ND; Nair K; McQueen RB
    Pharmacoeconomics; 2024 Mar; 42(3):319-328. PubMed ID: 37989969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.
    Weber A; Engelmaier A; Voelkel D; Pachlinger R; Scheiflinger F; Monahan PE; Rottensteiner H
    Mol Ther Methods Clin Dev; 2018 Sep; 10():29-37. PubMed ID: 30003118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver Gene Therapy.
    Nathwani AC; McIntosh J; Sheridan R
    Hum Gene Ther; 2022 Sep; 33(17-18):879-888. PubMed ID: 36082993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
    Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in the management of moderate-to-severe hemophilia B.
    Nazeef M; Sheehan JP
    J Blood Med; 2016; 7():27-38. PubMed ID: 27099538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
    Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
    N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.
    Djambas Khayat C
    J Blood Med; 2016; 7():275-282. PubMed ID: 27942241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.